TCS Q1 result: IT giant's net profit rises 6%, board recommends Rs 11/ share dividend
The company's revenue rose to Rs 63,437 crore, higher by 1.3 per cent as against Rs 62,613 crore in the year-ago period. However, TCS' revenue declined 3.1 per cent year-on-year (YoY) in constant currency. The company's operating margin was at 24.5 per cent, an expansion of 30 bps on a quarter-on-quarter basis.
TCS' board also recommended a dividend of Rs 11 per share.
'The continued global macro-economic and geo-political uncertainties caused a demand contraction. On the positive side, all the new services grew well. We saw robust deal closures during this quarter,' K Krithivasan, managing director and CEO, said. 'We remain closely connected to our customers to help them navigate the challenges impacting their business, through cost optimisation, vendor consolidation and AI-led business transformation,' he said.
TCS' shares remained subdued at Rs 3,382.30, down 0.06 per cent, on the BSE on Thursday. The share has fallen 26 per cent from the 52-week high level of Rs 4,585.
Aarthi Subramanian, Executive Director-President and COO, said 'Across industries, clients are increasingly shifting their focus from use case-based approach to ROI-led scaling of AI. We are investing across the AI ecosystem including infrastructure, data platform solutions, AI agents and business applications.'
TCS' workforce stood at 613,069 as on June 30, 2025. 'Our associates invested 15 million hours and acquired 1.3 million competencies in emerging technologies, enabling them to lead the transformation journey for our customers,' it said.
IT services' attrition was at 13.8 per cent for the last 12 months. 'We continued our investments in long term sustainable growth this quarter. We stayed agile and adapted to the dynamic environment, delivering steady margins. Our industry leading profitability alongside robust cash conversion, positions us well to make strategic investments for the future,' Samir Seksaria, chief financial officer, said.
According to TCS, this quarter, the AI and Data unit delivered robust growth, with enterprises advancing from pilots to scaled GenAI deployments. 'Demand was led by AI-led transformation, SDLC/IT-Ops automation, and data-platform modernisation. Our investments in WisdomNext, TCS' flagship AI platform are expanding with the addition of agentic AI capabilities. Strategic partnerships expanded, and our AI workforce with higher order skills exceeded 114,000, strengthening our leadership position in enterprise AI solutions,' it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Gujarat remains top exporting state in FY25 with ₹9.83 trn exports: FIEO
Gujarat retained its position as India's top exporting state in 2024-25, with outbound shipments worth Rs 9.83 lakh crore, accounting for 26.6 per cent of the country's total exports, FIEO said on Tuesday. It said despite a marginal dip from the previous year, Gujarat's exports remained significantly ahead of all other states, nearly Rs 4.3 lakh crore more than Maharashtra (Rs 5,57,271 crore), the second-ranked state. Maharashtra is followed by Tamil Nadu, Karnataka, Uttar Pradesh, Andhra Pradesh and Telangana, according to the analysis of the Federation of Indian Export Organisations (FIEO). "In 2024-25, Gujarat reaffirmed its leadership as India's top exporting state, accounting for Rs 9.83 lakh crore, which is 26.6 per cent of the country's total exports," it said. It added that Gujarat's export dominance continues to be driven by a few high-performing districts, with Jamnagar maintaining a commanding lead at Rs 3.63 lakh crore, largely owing to its petroleum and refinery exports. Jamnagar contributes over one-third of the state's total. The top five export commodities from the state are Petroleum Products, Gems and Jewellery, Organic Chemicals, Pharmaceuticals, and Engineering Goods (Machinery). In 2024-25, Uttar Pradesh contributes Rs 1.86 lakh crore to India's total exports of Rs 37.02 lakh crore. This accounts for 5 per cent of the country's total exports, positioning Uttar Pradesh as an important player in India's export landscape. "Uttar Pradesh has demonstrated a commendable diversification in its export markets, reaching both traditional and emerging economies across continents," it said, adding that the US continues to be the top export destination of the state.
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.
&w=3840&q=100)
Business Standard
a minute ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
